A 2-year naturalistic study on cognitive functioning in bipolar disorder

Acta Psychiatrica Scandinavica

Volumn 123, Issue 3, 2011, Pages 190-205

  Arts, B ^a   Jabben, N ^a   Krabbendam, L ^b   Van Os, J ^a,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bipolar disorder; Cognition; Disease characteristics; Medication; Mood

Indexed keywords

ADULT; ARTICLE; BIPOLAR DISORDER; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL;

ADULT; ATTENTION; BIPOLAR DISORDER; CASE-CONTROL STUDIES; COGNITION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; REGRESSION ANALYSIS; TIME FACTORS;

EID: 79551544963     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01601.x     Document Type: Article

References (100)

1. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-645.
2. Christensen MV, Kyvik KO, Kessing LV. Cognitive function in unaffected twins discordant for affective disorder. Psychol Med 2006;36:1119-1129.
3. Meyer SE, Carlson GA, Wiggs EA et al. A prospective study of the association among impaired executive functioning, childhood attentional problems, and the development of bipolar disorder. Dev Psychopathol 2004;16:461-476.
4. Pavuluri MN, Schenkel LS, Aryal S et al. Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients. Am J Psychiatry 2006;163:286-293.
5. Balanza-Martinez V, Tabares-Seisdebos R, Selva-Vera G et al. Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. Psychother Psychosom 2005;74:113-119.
6. Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry 2008;69:712-719.
7. Arts B, Jabben N, Krabbendam L, Van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol Med 2008;38:771-785.
8. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009;113:1-20.
9. Balanza-Martinez V, Rubio C, Selva-Vera G et al. Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: a systematic review. Neurosci Biobehav Rev 2008;32:1426-1438.
10. Krabbendam L, Marcelis M, Delespaul P, Jolles J, Van Os J. Single or multiple familial cognitive risk factors in schizophrenia? Am J Med Genet 2001;105:183-188.
11. Jabben N, Arts B, Krabbendam L, Van Os J. Investigating the association between neurocognition and psychosis in bipolar disorder: further evidence for the overlap with schizophrenia. Bipolar Disord 2009;11:166-177.
12. Quraishi S, Walshe M, Mcdonald C et al. Memory functioning in familial bipolar I disorder patients and their relatives. Bipolar Disord 2009;11:209-214.
13. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord 2006;8:103-116.
14. Savitz JB, Van Der Merwe L, Stein DJ, Solms M, Ramesar RS. Neuropsychological task performance in bipolar spectrum illness: genetics, alcohol abuse, medication and childhood trauma. Bipolar Disord 2008;10:479-494.
15. Vonk R, Van Der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry 2007;62:135-140.
16. Davis JD, Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol 2007;32:49-65.
17. Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest 2007;30:363-366.
18. Prohaska ML, Stern RA, Steketee MC. Lithium-thyroid interactive hypothesis of neuropsychological deficits: a review and proposal. Depression 1995;2:241-251.
19. Burdick KE, Endick CJ, Goldberg JF. Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res 2005;136:43-50.
20. Martinez-Aran A, Vieta E, Colom F et al. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom 2005;74:295-302.
21. APA. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC, 1994.
22. Mcguffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991;48:764-770.
23. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992;49:615-623.
24. Maxwell ME. Manual for the family interview for genetic studies (FIGS). Bethesda, MD: National Institute of Mental Health, 1992.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
26. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435.
27. Lukoff D, Nuechterlein KH, Ventura J. Manual for the expanded BPRS. Schizophr Bull 1986;12:594-602.
28. Leverich GS, Nolen WA, Rush AJ et al. The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affect Disord 2001;67:33-44.
29. Broadbent DE, Cooper PF, Fitzgerald P, Parkes KR. The Cognitive Failure Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982;21:1-16.
30. Luteijn F, Van Der Ploeg FAE. Handleiding Groninger intelligentietest (GIT). Lisse, the Netherlands: Swets and Zeitlinger, 1983.
31. Wechsler D. Wechsler adult intelligence scale-revised. New York: Psychological Corporation, 1981.
32. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Paris: Presses Universitaires de France, 1964.
33. Nestor PG, Faux SF, Mccarley RW, Shenton ME, Sands SF. Measurement of visual sustained attention in schizophrenia using signal detection analysis and a newly developed computerized CPT task. Schizophr Res 1990;3:329-332.
34. Smid HG, De Witte MR, Homminga I, Van Den Bosch RJ. Sustained and transient attention in the continuous performance task. J Clin Exp Neuropsychol 2006;28:859-883.
35. Eriksen CW, Schultz DW. Information processing in visual search: a continuous flow conception and experimental results. Percept Psychophys 1979;25:249-263.
36. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation. Tucson: Neuropsychology, 1985.
37. Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale. San Antonio, TX: Psychological Corporation, 1997.
38. STATACORP. STATA statistical software. Release 8.0 ed. College Station, TX, 2002.
39. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986;73:751-754.
40. Rubin DB. Inference and missing data. Biometrika 1976;63:581-592.
41. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 2002;7:147-177.
42. Royston P. Multiple imputation of missing values: update of ice. Stata J 2005;5:527-536.
43. Squire LR, Zola SM. Structure and function of declarative and nondeclarative memory systems. Proc Natl Acad Sci U S A 1996;93:13515-13522.
44. Van Gorp WG, Altshuler L, Theberge DC, Mintz J. Declarative and procedural memory in bipolar disorder. Biol Psychiatry 1999;46:525-531.
45. Altshuler LL, Ventura J, Van Gorp WG, Green MF, Theberge DC, Mintz J. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry 2004;56:560-569.
46. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 2008;8:57-64.
47. Engelsmann F, Katz J, Ghadirian AM, Schachter D. Lithium and memory: a long-term follow-up study. J Clin Psychopharmacol 1988;8:207-212.
48. Rast P, Zimprich D, Van Boxtel M, Jolles J. Factor structure and measurement invariance of the cognitive failures questionnaire across the adult life span. Assessment 2009;16:145-158.
49. Burdick KE, Goldberg JF, Harrow M, Faull RN, Malhotra AK. Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis 2006;194:255-260.
50. Kravariti E, Schulze K, Kane F et al. Stroop-test interference in bipolar disorder. Br J Psychiatry 2009;194:285-286.
51. Harmer CJ, Clark L, Grayson L, Goodwin GM. Sustained attention deficit in bipolar disorder is not a working memory impairment in disguise. Neuropsychologia 2002;40:1586-1590.
52. Clark L, Iversen SD, Goodwin GM. Sustained attention deficit in bipolar disorder. Br J Psychiatry 2002;180:313-319.
53. Ancin I, Santos JL, Teijeira C et al. Sustained attention as a potential endophenotype for bipolar disorder. Acta Psychiatr Scand 2010;122:235-245.
54. Swann AC, Lijffijt M, Lane SD, Steinberg JL, Moeller FG. Severity of bipolar disorder is associated with impairment of response inhibition. J Affect Disord 2009;116:30-36.
55. Schouws SN, Comijs HC, Stek ML et al. Cognitive impairment in early and late bipolar disorder. Am J Geriatr Psychiatry 2009;17:508-515.
56. Martinez-Aran A, Vieta E, Colom F et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004;6:224-232.
57. Thompson JM, Gallagher P, Hughes JH et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005;186:32-40.
58. Van Gorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gen Psychiatry 1998;55:41-46.
59. Strakowski SM, Fleck DE, Delbello MP et al. Characterizing impulsivity in mania. Bipolar Disord 2009;11:41-51.
60. Roiser JP, Cannon DM, Gandhi SK et al. Hot and cold cognition in unmedicated depressed subjects with bipolar disorder. Bipolar Disord 2009;11:178-189.
61. Savitz J, Van Der Merwe L, Stein DJ, Solms M, Ramesar R. Neuropsychological status of bipolar I disorder: impact of psychosis. Br J Psychiatry 2009;194:243-251.
62. Martinez-Aran A, Torrent C, Tabares-Seisdedos R et al. Neurocognitive impairment in bipolar patients with and without history of psychosis. J Clin Psychiatry 2008;69:233-239.
63. Selva G, Salazar J, Balanza-Martinez V et al. Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning? J Psychiatr Res 2007;41:265-272.
64. Goldberg JF, Chengappa KN. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord 2009;11(Suppl. 2):123-137.
65. Holmes MK, Erickson K, Luckenbaugh DA et al. A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disord 2008;10:806-815.
66. Clark L, Kempton MJ, Scarna A, Grasby PM, Goodwin GM. Sustained attention-deficit confirmed in euthymic bipolar disorder but not in first-degree relatives of bipolar patients or euthymic unipolar depression. Biol Psychiatry 2005;57:183-187.
67. Goswami U, Sharma A, Varma A et al. The neurocognitive performance of drug-free and medicated euthymic bipolar patients do not differ. Acta Psychiatr Scand 2009;120:456-463.
68. Strakowski SM, Adler CM, Holland SK, Mills N, Delbello MP. A preliminary FMRI study of sustained attention in euthymic, unmedicated bipolar disorder. Neuropsychopharmacology 2004;29:1734-1740.
69. Fountoulakis KN, Vieta E, Bouras C et al. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol 2008;11:269-287.
70. Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology (Berl) 2003;170:225-234.
71. Jamrozinski K, Gruber O, Kemmer C, Falkai P, Scherk H. Neurocognitive functions in euthymic bipolar patients. Acta Psychiatr Scand 2009;119:365-374.
72. Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009;11(Suppl. 2):92-109.
73. Savitz J, Nugent AC, Bogers W et al. Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage 2010;49:2966-2976.
74. Goldberg JF, Burdick KE. Cognitive side effects of anticonvulsants. J Clin Psychiatry 2001;62(Suppl. 14):27-33.
75. Senturk V, Goker C, Bigic A et al. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord 2007;9(Suppl. 1):136-144.
76. Daban C, Martinez-Aran A, Torrent C et al. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J Clin Psychopharmacol 2006;26:178-181.
77. Haldane M, Jogia J, Cobb A, Kozuch E, Kumari V, Frangou S. Changes in brain activation during working memory and facial recognition tasks in patients with bipolar disorder with Lamotrigine monotherapy. Eur Neuropsychopharmacol 2008;18:48-54.
78. Donaldson S, Goldstein LH, Landau S, Raymont V, Frangou S. The Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. J Clin Psychiatry 2003;64:86-93.
79. Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633-647.
80. Houthoofd SA, Morrens M, Sabbe BG. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther 2008;30:1565-1589.
81. Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64:1115-1122.
82. Bilik E, Akdede BB, Hidiroglu C et al. Neurocognitive functions in euthymic bipolar patients on mono versus polypharmacy in comparison to healthy controls. Bipolar Disord 2009;11(Suppl.1):21.
83. Martino DJ, Marengo E, Igoa A et al. Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1 year follow-up study. J Affect Disord 2009;116:37-42.
84. Wingo AP, Harvey PD, Baldessarini RJ. Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord 2009;11:113-125.
85. Marangell LB, Dennehy EB, Miyahara S et al. The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord 2009;114:58-67.
86. Baldini M, Colasanti A, Orsatti A, Airaghi L, Mauri MC, Cappellini MD. Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: the effects of l-thyroxine. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:854-859.
87. Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E. Neuropsychological profile in bipolar disorder: a preliminary study of monotherapy lithium-treated euthymic bipolar patients evaluated at a 2-year interval. Acta Psychiatr Scand 2008;118:373-381.
88. Deckersbach T, Ametrano RM, Carlson LE, Lund HG, Sachs GS, Nierenberg AA. Cognitive rehabilitation for bipolar disorder: preliminary results and predictors of treatment response. Bipolar Disord 2009;11(Suppl. 1):32-33.
89. Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord 2005;7:216-235.
90. Weickert TW, Goldberg TE, Mishara A et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004;56:677-682.
91. Rybakowski JK, Suwalska A, Skibinska M et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005;38:166-170.
92. Tabares-Seisdedos R, Escamez T, Martinez-Gimenez JA et al. Variations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from mediterranean Spain: a preliminary study. Neuroscience 2006;139:1289-1300.
93. Antila M, Tuulio-Henriksson A, Kieseppa T et al. Heritability of cognitive functions in families with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B:802-808.
94. Soronen P, Silander K, Antila M et al. Association of a nonsynonymous variant of DAOA with visuospatial ability in a bipolar family sample. Biol Psychiatry 2008;64:438-442.
95. Pietilainen OP, Paunio T, Loukola A et al. Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins. Am J Med Genet B Neuropsychiatr Genet 2009;150B:683-692.
96. Dewachter I, Ris L, Jaworski T et al. GSK3beta, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9. Neurobiol Dis 2009;35:193-200.
97. Zhou R, Gray NA, Yuan P et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005;25:4493-4502.
98. Burdick KE, Funke B, Goldberg JF et al. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord 2007;9:370-376.
99. Rybakowski JK, Borkowska A, Skibinska M, Hauser J. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Mol Psychiatry 2006;11:122-124.
100. Frey BN, Andreazza AC, Cereser KM et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006;79:281-286.